Study guide
10.2 Cervical Cancer Screening & ASCCP Algorithms
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
10.2 Cervical Cancer Screening & ASCCP Algorithms
Key Takeaways Explain This Topic AI
Cervical cancer screening begins at age 21 with cervical cytology (Pap smear) alone every 3 years; hrHPV testing (alone or co-testing) is strictly contraindicated under age 30 due to high rates of transient, self-resolving HPV infections.
For average-risk women aged 30 to 65 years, the USPSTF endorses three equivalent Grade A strategies: cytology alone every 3 years, high-risk HPV (hrHPV) testing alone every 5 years, or cytology plus hrHPV co-testing every 5 years.
Screening ceases at age 65 (USPSTF Grade D) provided adequate prior negative screening is documented (3 consecutive negative cytologies or 2 consecutive negative hrHPV/co-tests within 10 years, most recent within 5 years) and no history of CIN 2+ within the preceding 20 years.
The 2019 ASCCP risk-based consensus guidelines establish an immediate CIN 3+ risk threshold of >=4.0% for immediate colposcopy, an immediate risk of 0.55% to 3.9% for 1-year surveillance, and an immediate risk <0.15% for return to 5-year routine screening.
In pregnant patients, colposcopy is safe and indicated for high-grade cytology or high-risk findings, but endocervical curettage (ECC) and endometrial biopsy (EMB) are strictly contraindicated due to the risk of membrane rupture and severe hemorrhage.
Last updated: September 2026
Pathophysiology & Virology of Cervical Neoplasia
Virtually all cervical malignancies (>99%) are etiologically linked to persistent mucosal infection with oncogenic high-risk Human Papillomavirus (hrHPV) types:
Viral Subtypes : HPV types 16 and 18 account for approximately 70% of invasive cervical carcinomas and 50% of cervical intraepithelial neoplasia grade 3 (CIN 3) lesions globally. Non-16/18 high-risk types (such as 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) account for the remaining 20% to 30%. Low-risk HPV types (predominantly 6 and 11) cause benign anogenital condylomata acuminata and transient low-grade dysplasias, but possess no oncogenic potential.
Molecular Mechanisms of Oncogenesis : High-risk HPV genomes integrate into host cellular DNA, leading to constitutive over-expression of two potent viral oncoproteins:
E6 Oncoprotein : Binds to host cellular p53 tumor suppressor protein , recruiting E6-associated protein (E6AP) ubiquitin ligase to trigger targeted proteasomal degradation of p53. This halts apoptosis in cells harboring DNA damage.
E7 Oncoprotein : Binds to and phosphorylates the retinoblastoma protein (pRb) , disrupting the pRb-E2F complex. Unbound E2F transcription factors enter the nucleus, forcing continuous G1-to-S phase cell cycle transition and driving unregulated cellular proliferation.
Natural History & Viral Clearance : In adolescents and young adults, HPV infection is an endemic, sexually acquired condition with a lifetime cumulative incidence exceeding 80%. However, in immunocompetent hosts younger than 30, 80% to 90% of incident HPV infections are spontaneously cleared or suppressed to undetectable levels by cell-mediated immunity within 12 to 24 months. Neoplastic transformation from transient viral infection to precancerous CIN 3 requires persistent hrHPV infection over years to decades.
USPSTF Cervical Cancer Screening Recommendations by Age Group
The USPSTF provides clear, age-stratified guidelines for cervical cancer screening in asymptomatic, average-risk individuals with a cervix:
1. Age <21 Years: Screening Strictly Contraindicated (USPSTF Grade D)
Regardless of the age of coital debut, number of sexual partners, or other behavioral risk factors, screening is not recommended in individuals younger than 21.
Rationale : Invasive cervical carcinoma is extraordinarily rare in this demographic (<1 to 2 cases per 1,000,000). Although HPV infection rates are high in sexually active adolescents, virtually all resulting dysplastic changes represent transient, self-limiting CIN 1 that regresses spontaneously. Screening adolescents produces extreme harm through overtreatment: excisional cervical procedures (LEEP/cold knife conization) permanently compromise cervical tensile integrity, dramatically increasing future risks of cervical insufficiency, second-trimester spontaneous abortion, and preterm premature rupture of membranes (PPROM).
2. Age 21 to 29 Years: Cytology Alone Every 3 Years (USPSTF Grade A)
Recommended Modality : Cervical cytology (liquid-based or conventional Pap smear) alone every 3 years .
Strict Rule on hrHPV Testing : High-risk HPV screening (either as primary standalone HPV testing or as co-testing with cytology) is strictly NOT recommended for routine screening in women aged 21 to 29. Because transient hrHPV infections are exceedingly common in this cohort, routine HPV testing generates high rates of false-positive results that prompt unnecessary colposcopies and emotional distress without improving cancer prevention. (Reflex HPV testing is permitted only for triaging atypical squamous cells of undetermined significance [ASC-US]).
3. Age 30 to 65 Years: Three Equivalent Grade A Strategies (USPSTF Grade A)
For average-risk women aged 30 to 65 years, the USPSTF endorses three acceptable screening strategies :
Cervical Cytology Alone Every 3 Years : Reliable, time-tested strategy with excellent specificity.
High-Risk HPV (hrHPV) Alone Every 5 Years : Performed using an FDA-approved primary hrHPV screening assay. Primary hrHPV testing exhibits higher clinical sensitivity (>90%) for high-grade cervical precancer (CIN 3+) compared to single-timepoint cytology (50–70%), permitting safe extension of screening intervals to 5 years.
Cervical Cytology + hrHPV Co-Testing Every 5 Years : Combines cytologic morphological examination with molecular viral detection.
Clinical Guideline Nuance : The American Cancer Society (ACS) guidelines preferentially recommend primary hrHPV testing alone every 5 years beginning at age 25. However, on the ABFM board examination, the USPSTF guidelines are the primary benchmark : screening begins at age 21 with cytology alone every 3 years, and hrHPV testing is incorporated only beginning at age 30.
- Discontinuing Screening: Age 65 Stopping Rules & Hysterectomy Status
- The Age 65 Cessation Criteria (USPSTF Grade D)
Routine cervical cancer screening should be discontinued at age 65 provided the patient fulfills both of the following prerequisites:
Documented Adequate Prior Negative Screening :
- Three consecutive negative cervical cytology results , OR
- Two consecutive negative hrHPV or co-test results ,
Within the preceding 10 years , with the most recent test performed within the last 5 years .
Absence of High-Grade Precancer History :
No history of CIN 2, CIN 3, or adenocarcinoma in situ (AIS) within the preceding 20 years .
The 20-Year Rule for Prior CIN 2+ : If a patient has a documented historical diagnosis of CIN 2, CIN 3, or AIS, routine cervical screening must continue for at least 20 years from the date of histologic regression or surgical treatment , even if that surveillance timeline extends well beyond age 65 (e.g., a woman treated for CIN 3 at age 52 must continue routine screening until at least age 72).
Screening Following Hysterectomy
Total Hysterectomy for Benign Disease (USPSTF Grade D) : In women who have undergone a complete surgical removal of both the uterine corpus and the cervix for benign conditions (such as leiomyomas, adenomyosis, endometriosis, or pelvic organ prolapse) and who have no historical diagnosis of CIN 2, CIN 3, AIS, or cervical cancer , routine screening (vaginal cuff cytology) is permanently discontinued .
Supracervical Hysterectomy : In women whose cervix remains anatomically intact (subtotal or supracervical hysterectomy), routine cervical screening must continue according to standard age-based recommendations.
Hysterectomy with History of CIN 2, CIN 3, or AIS : In women who underwent total hysterectomy but have a history of high-grade precancer, the vaginal cuff remains vulnerable to HPV-mediated vaginal intraepithelial neoplasia (VaIN). Routine vaginal cuff screening must continue for at least 20 years following the date of treatment.
The 2019 ASCCP Consensus Guidelines: Risk-Based Management
In 2019, the American Society for Colposcopy and Cervical Pathology (ASCCP), in partnership with the National Cancer Institute (NCI), completely revamped cervical management from historical result-based algorithms to a modern quantitative risk-based framework .
The Foundational Principle: "Equal Management for Equal Risk"
Clinical management is dictated by a patient's calculated risk of underlying CIN 3+ (the surrogate for cervical cancer risk), rather than the isolated cytologic result. Risk estimates integrate current screening results (cytology and HPV status), prior screening history, and HPV genotyping.
Master ASCCP Clinical Action Thresholds
Immediate CIN 3+ Risk Threshold Clinical Action / Management Recommendation Representative Clinical Scenarios
>= 60% Expedited Treatment Preferred without prior biopsy (LEEP / cone) OR Colposcopy with biopsy HSIL cytology + HPV 16 positive in patients >=25 with completed childbearing
25% to 59% Expedited Treatment OR Colposcopy with directed biopsies acceptable HSIL cytology + hrHPV positive (unspecified type); ASC-H + HPV 16 positive
>= 4.0% Immediate Diagnostic Colposcopy with directed biopsies and endocervical sampling ASC-US with hrHPV positive; LSIL with hrHPV positive; NILM with HPV 16/18 positive
0.55% to 3.9% 1-Year Surveillance (repeat hrHPV or co-testing in 12 months) LSIL with negative hrHPV co-test; Persistent HPV positive with normal cytology
0.15% to 0.54% 3-Year Surveillance (repeat co-testing in 3 years) ASC-US with negative hrHPV co-test; Normal cytology with negative prior history
< 0.15% 5-Year Routine Return (resume standard population screening interval) Negative hrHPV screening test; Negative co-test (NILM / HPV negative)
- Algorithmic Management of Specific Cytologic Abnormalities
- 1. Atypical Squamous Cells of Undetermined Significance (ASC-US)
Preferred Triaging Strategy : Reflex high-risk HPV testing from the liquid-based cytology vial.
If hrHPV is Positive : Immediate CIN 3+ risk is approximately 4.5% (surpassing the 4.0% colposcopy threshold). Management: Immediate Colposcopy .
If hrHPV is Negative : 5-year CIN 3+ risk is <0.5%. Management: Defer colposcopy; resume routine screening (repeat co-test in 3 years).
Special Population (Age 21 to 24 Years) : In young women aged 21 to 24, HPV prevalence is high and regression rates exceed 80%. If cytology reveals ASC-US (regardless of HPV status) or LSIL, repeat cervical cytology in 12 months ; colposcopy is deferred unless abnormality progresses to HSIL/ASC-H or persists for 2 consecutive years.
2. Low-Grade Squamous Intraepithelial Lesion (LSIL)
In women aged >=25 years :
If hrHPV is positive or untested: Immediate CIN 3+ risk is approximately 4.3% . Management: Immediate Colposcopy .
If hrHPV is negative (on concurrent co-test): Immediate CIN 3+ risk is only 1.1% (well below the 4.0% threshold). Management: Repeat co-testing in 1 year ; defer immediate colposcopy.
In women aged 21 to 24 years : Repeat cytology in 12 months .
3. Atypical Squamous Cells, Cannot Exclude High-Grade (ASC-H)
Represents a cytologic pattern with high suspicion for underlying high-grade precancer (underlying CIN 2/3 prevalence is 12% to 25%).
Management: Immediate Diagnostic Colposcopy for all patients regardless of HPV status. Reflex HPV testing cannot be used to triage ASC-H.
4. High-Grade Squamous Intraepithelial Lesion (HSIL)
Carries an immediate CIN 3+ risk between 25% and 60%.
Management in non-pregnant patients aged >=25 years :
Expedited Treatment (LEEP / Cold Knife Conization) without prior biopsy is acceptable and preferred for patients with completed childbearing or high-risk HPV 16/18 positivity.
Alternatively, diagnostic colposcopy with endocervical assessment is acceptable.
In patients aged 21 to 24 years : Immediate diagnostic colposcopy is mandatory; expedited excisional treatment without biopsy is contraindicated.
5. Atypical Glandular Cells (AGC)
Represents a perilous cytologic finding reflecting potential neoplasia of the endocervical canal or endometrium (underlying pathology includes adenocarcinoma in situ [AIS], invasive cervical adenocarcinoma, and endometrial adenocarcinoma).
Initial Management for ALL Patients with AGC (AGC-NOS, AGC favor neoplastic):
Immediate Colposcopy with Endocervical Curettage (ECC) .
Mandatory Endometrial Biopsy (EMB) Indications :
All patients aged >=35 years with AGC.
Patients aged <35 years with clinical risk factors for endometrial neoplasia: unexplained abnormal uterine bleeding, chronic anovulation (PCOS), morbid obesity (BMI >=35), diabetes mellitus, or tamoxifen therapy.
6. HPV Genotype 16 or 18 Positivity with Normal Cytology (NILM)
HPV 16 and 18 possess extreme oncogenic velocity and are responsible for the vast majority of aggressive cervical adenocarcinomas that evade cytologic exfoliation.
If a screening co-test reveals NILM (Negative for Intraepithelial Lesion or Malignancy) but HPV 16 or HPV 18 is positive , the immediate CIN 3+ risk is 4.1% to 8.0% (exceeding the 4.0% threshold).
Management: Immediate Diagnostic Colposcopy . Deferring evaluation to 1-year surveillance is dangerous and unacceptable.
- Special Clinical Populations: Pregnancy & Immunosuppression
- Cervical Evaluation During Pregnancy
Physiological Changes : High gestational estrogen levels induce marked cervical stromal hypervascularity, eversion of the squamocolumnar junction (physiologic ectropion), stromal softening, and exuberant decidual transformation that can mimic invasive neoplasia.
Colposcopy Safety : Diagnostic colposcopy is completely safe during pregnancy and should be performed by an experienced clinician for high-grade cytology (HSIL, ASC-H, AGC) or high-risk findings (immediate CIN 3+ risk >=4.0%).
Directed Exocervical Biopsies : Biopsy of frankly suspicious exocervical lesions may be performed during pregnancy, but carries an increased risk of brisk bleeding. Hemostasis is obtained using Monsel's solution (ferric subsulfate) or silver nitrate.
Absolute Contraindications in Pregnancy :
Endocervical Curettage (ECC) is STRICTLY CONTRAINDICATED : Curettage of the endocervical canal disrupts the mucus plug, risks mechanical rupture of the amniotic membranes, introduces ascending chorioamnionitis, and triggers catastrophic preterm delivery or fetal demise.
Endometrial Biopsy (EMB) is STRICTLY CONTRAINDICATED : Mechanical instrumentation of the endometrial cavity disrupts the gestational sac, causing immediate pregnancy loss.
Diagnostic excisional procedures (LEEP/cold knife cone) are contraindicated unless invasive cervical cancer is strongly suspected on directed biopsy.
Postpartum Follow-up : Patients with cervical precancer managed conservatively during pregnancy must undergo complete repeat colposcopy and cytology at 6 to 12 weeks postpartum .
Immunocompromised Patients (HIV, Solid Organ Transplant, Systemic Autoimmunity)
Immunosuppressed patients have impaired cellular immune clearance, experiencing high persistent hrHPV infection rates and accelerated progression to invasive cancer.
Screening Initiation : Screening begins at the onset of sexual debut or at the time of HIV diagnosis, even if younger than 21.
Surveillance Protocol : Perform cervical cytology alone annually for 3 consecutive years; if all 3 results are normal, extend the screening interval to every 3 years .
Co-Testing : Cytology and hrHPV co-testing is permitted starting at age 30, repeated every 3 years if negative.
Lifelong Screening Mandate : Cervical cancer screening in immunocompromised patients continues lifelong and does not stop at age 65.